Whitehawk Therapeutics (WHWK) Current Assets (2010 - 2026)

Whitehawk Therapeutics (WHWK) has 15 years of Current Assets data on file, last reported at $125.5 million in Q1 2026.

• On a quarterly basis, Current Assets fell 46.03% year-over-year to $125.5 million in Q1 2026; TTM through Mar 2026 was $125.5 million, a 46.03% decrease from a year earlier, with the FY2025 full-year figure at $149.0 million, up 143.14% from the prior year.
• Current Assets for Q1 2026 stood at $125.5 million, down from $149.0 million in the prior quarter.
• Over the last five years, Current Assets for WHWK reached as high as $232.6 million in Q1 2025 and fell as low as $61.3 million in Q4 2024.
• Historically, Current Assets has averaged $140.1 million across 5 years, with a median of $135.6 million in 2022.
• Across the five-year window, Current Assets jumped 232.49% in 2022 and tumbled 50.81% in 2024, its largest moves.
• Year by year, Current Assets stood at $180.0 million in 2022, then sank by 30.8% to $124.6 million in 2023, then sank by 50.81% to $61.3 million in 2024, then soared by 143.14% to $149.0 million in 2025, then dropped by 15.75% to $125.5 million in 2026.
• Per Business Quant data, the three most recent Current Assets figures were $125.5 million in Q1 2026, $149.0 million in Q4 2025, and $165.0 million in Q3 2025.